Search All UT System Experts

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

Muhammad Shaalan Beg, Xiumei Huang, Molly A. Silvers, David E. Gerber, Joyce Bolluyt, Venetia Sarode, Farjana Fattah, Ralph J. Deberardinis, Matthew E. Merritt, Xian Jin Xie, Richard Leff, Daniel Laheru, David A. Boothman

Research output: Contribution to journal › Comment/debate › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences